Tryptamine Therapeutics (ENP) AI Stock Analysis

Entropy Neurodynamics Limited has disclosed a change in director Herwig Janssen’s interests, with the issuance of 623,441 ordinary fully paid shares in lieu of cash fees for services rendered between July and September 2026. This equity-based p...

Entropy Neurodynamics Limited has issued 623,441 fully paid ordinary shares to its directors in lieu of cash payment of directors’ fees, as previously approved at its 13 November 2025 Annual General Meeting. The company has lodged the associate...

Entropy Neurodynamics Limited, an ASX-listed company in the neurotechnology and neuroscience domain, structures director remuneration so that fees may be paid in shares rather than cash. The use of ordinary fully paid shares for board compensation al...

Entropy Neurodynamics Limited has released key documents for its 2026 Annual General Meeting, including the notice of meeting, a letter of access and proxy form, signalling the next formal step in its governance calendar as a recently listed clinical...

Entropy Neurodynamics Limited has scheduled its 2026 Annual General Meeting for 12 November 2026 at 4:00pm AEDT in Hawthorn East, Victoria, and has set 24 September 2026 as the closing date for director nominations. The company is also encouraging sh...

Entropy Neurodynamics Limited, a clinical-stage biotech in Melbourne, is developing precision-controlled psychedelic therapies, led by its IV-infused psilocin candidate TRP-8803 for treatment-resistant binge eating disorder. The company is building a...

Entropy Neurodynamics Limited, a clinical-stage biotech focused on psilocin-based psychedelic-assisted therapies, is advancing proprietary formulations aimed at treating conditions with unmet medical needs. Its lead candidate, TRP-8803, delivers psil...

Entropy Neurodynamics Limited has lodged its Appendix 4G and corporate governance statement with the ASX for the financial year ended 30 June 2026, confirming board approval and compliance with the exchange’s disclosure framework. The company h...

Entropy Neurodynamics Limited operates in the neurodynamics and therapeutics sector, with related entities Tryp Therapeutics Inc in Canada and Tryp Therapeutics (USA) Inc in the U.S. preparing their accounts under IFRS Accounting Standards. The group...

Entropy Neurodynamics has signed a pre-Clinical Trial Agreement with the University of California, San Francisco to run a U.S. Phase 2 trial comparing its IV psilocin candidate TRP-8803 against escitalopram in up to 80 young adults with Major Depress...

Entropy Neurodynamics Limited has lodged a new application with the ASX for the quotation of 1,000,000 ordinary fully paid shares under its existing ENP code, with an issue date of August 21, 2026. The move formalizes the listing of these additional...

Entropy Neurodynamics has requested a trading halt on its ordinary shares from the start of ASX trading on 24 August 2026, with the halt to remain in place until either 26 August 2026 or the release of a pending announcement. The move signals a forth...

Entropy Neurodynamics has signed a Development and Manufacturing Services Agreement with BioCina to produce its proprietary TRP-8803 intravenous psilocin formulation under GMP conditions. The deal secures access to BioCina’s TGA-licensed, FDA-...

Entropy Neurodynamics Limited has disclosed a change in director Herwig Janssen’s holdings, reflecting the issuance of additional ordinary fully paid shares. The update was lodged under Australian Securities Exchange requirements, detailing mov...

Entropy Neurodynamics has issued 766,871 fully paid ordinary shares to directors in lieu of cash fees, as previously approved at its November 2025 annual general meeting, and has lodged the relevant Appendix 2A with the ASX. The company confirmed it...

Entropy Neurodynamics Limited has applied to the ASX for quotation of 766,871 ordinary fully paid shares, to be issued on August 7, 2026. These shares are being issued in lieu of cash payment for directors’ fees, following prior approval by sha...

Tryp Therapeutics, presented under the Entropy Neurodynamics banner at the Bioshares 2026 Investor Roadshow, is highlighting world-first clinical results in treating resistant binge eating disorder using psychedelic-assisted approaches. The company p...